sNN 0029

Drug Profile

sNN 0029

Alternative Names: rhVEGF165 - Newron Pharmaceuticals; sNN-0029; Telbermin - Newron Pharmaceuticals

Latest Information Update: 11 Mar 2016

Price : $50

At a glance

  • Originator NeuroNova AB
  • Developer Newron Pharmaceuticals
  • Class Growth factors
  • Mechanism of Action Neuron stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Amyotrophic lateral sclerosis

Most Recent Events

  • 26 Jan 2016 Newron terminates a phase I/II trial in Amyotrophic lateral sclerosis in Belgium (NCT01384162)
  • 26 Jan 2016 Newron terminates two phase I trials in Amyotrophic lateral sclerosis in Belgium and the Netherlands (NCT01999803; NCT02269436)
  • 31 Oct 2015 Discontinued - Phase-II for Amyotrophic lateral sclerosis in Belgium (Intracerebral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top